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Abstract 
Purpose: To assess the risk factors and outcomes associated with fungemia caused by the six most commonly occur‑
ring Candida species in patients with and without malignancies.
Methods: Analysis of the episodes of fungemia due to common Candida species in adults, based on an active 
hospital‑based surveillance program (Paris area, France, 2002 to 2014).
Results: Of the 3417 patients (3666 isolates), 1164 (34.1%) had a solid tumor (45.7% digestive tract) and 586 (17.1%) 
a hematological malignancy (41.8% lymphoma, 33.5% acute leukemia). The hematology patients were significantly 
younger, more often pre‑exposed to antifungals, more often infected by C. tropicalis, C. krusei, or C. kefyr, and more 
often treated in the first instance with an echinocandin. Compared with inpatients who were not in ICU at the time of 
fungemia, those in ICU were less frequently infected by C. parapsilosis (p < 0.02), had more recent surgery (p < 0.03), 
and died more frequently before day 8 and day 30 (p < 0.0001). An increase in crude mortality over time in ICU was 
observed only in oncology patients (p < 0.04). For all patients, lack of prescription of antifungals despite knowledge of 
positive blood culture increased the risk of death. The odds of being infected by a given Candida species compared 
with C. albicans were uneven regarding age, gender, type of malignancy, hospitalization in ICU, central venous cath‑
eter, HIV status, intravenous drug addiction, and previous exposure to antifungal drugs. Compared with C. albicans, 
C. glabrata (OR = 0.69 [0.54–0.89]) and C. parapsilosis (OR = 0.49 [0.35–0.67]) were associated with a decreased risk of 
death by day 8 and day 30.
Conclusion: The clinical context of underlying malignancy and hospitalization in ICU may be relevant to the initial 
management of candidemia.
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Take-home message: The type of underlying malignancy (solid vs 
hematological) and hospitalization in vs outside ICU impact differentially 
on fungemia by different species of Candida.
Introduction
Candidemia currently represent up to 10% of nosoco-
mial bloodstream infections [1–3] with associated mor-
tality, increased length of stay and cost [4]. It is therefore 
a public health concern everywhere [5]. Among the risk 
factors, hematological malignancies and solid tumors 
represent a large proportion [6, 7]. Many changes have 
occurred over the last decade with the increased inci-
dence of fungemia due to Candida glabrata at least in 
some settings [8, 9], the availability of echinocandins 
653
[10–12] and new broad-spectrum triazoles prophylaxis 
in hematology, the implementation of management 
guidelines [13, 14], and better suspicion/awareness of 
clinicians. Whether or not all these changes impact the 
characteristics and outcome of candidemia among adults 
with malignancy needs to be further investigated. Several 
retrospective monocentric studies described the local 
epidemiology of candidemia among patients with malig-
nancy [15–17] and only two recent prospective studies 
concerned cancer patients [18, 19]. No study has ever 
analyzed the characteristics and outcome of infection in 
patients with solid tumor or hematological malignancy 
developing candidemia and the impact of their hospitali-
zation in intensive care unit (ICU) [20].
We launched in 2002 a large prospective hospital-based 
surveillance program on patients developing candidemia 
in the Paris area and recently reported the characteris-
tics of patients hospitalized in ICU [9] and of those who 
developed fungemia due to rare yeasts [21]. The goal of 
the present study was to characterize over more than a 
decade Candida spp. distribution and prognostic factors 
according to underlying malignancy and ICU hospitaliza-
tion. We also determined if the context associated with 
non-albicans candidemia was suggestive enough to help 
the clinician with the first therapeutic choice.
Materials and methods
Population studied and isolates characterization
A sustainable active surveillance program on yeast 
fungemia (YEASTS program) was implemented with 
participation of 26 short-stay university hospitals in 
the Paris area. All blood cultures positive with yeasts 
were notified, with data completed on a standardized 
form, on a secured website. All isolates were sent to the 
French National Reference Center for Invasive Mycoses 
and Antifungals (NRCMA). There, purity and identifica-
tion were assessed [22] and in vitro susceptibility testing 
performed according to the EUCAST procedure [23]. 
The current analysis concerns the incident episodes of 
candidemia recorded in patients aged at least 15  years 
old between October 2002 and December 2014, and due 
to C.  albicans, C. glabrata, C. tropicalis, C. parapsilosis 
complex that includes C. metapsilosis and C. orthopsilo-
sis (hereafter named C.  parapsilosis), C. krusei (current 
name Pichia kudriavzevii), and C.  kefyr (current name 
Kluyveromyces marxianus). Single and mixed (>1 spe-
cies) infections were considered.
Definitions
The date of candidemia was that of blood sampling 
(day  0). Patients were assigned to one of three groups: 
hematological malignancy, solid tumor (“oncology”), or 
“no malignancy”. Surgery and antifungal preexposure 
(whatever dosage and duration) occurring within 30 days 
prior to candidemia were recorded. First-line antifungal 
therapy was analyzed only for patients for whom the pos-
itivity of the blood culture was known before death and 
was categorized into four groups: “fluconazole”, “echi-
nocandins”, “other treatments” (all other antifungals and 
drug combinations), and “no antifungals”. Antifungal 
drug resistance was defined as minimum inhibitory con-
centration (MIC) ≥8 mg/L [24] for fluconazole and MIC 
>0.25 mg/L for caspofungin [25].
Statistical analysis
Univariate analysis was based on Chi2 or Fisher’s exact 
test when needed for discrete variables. Kruskal–Wallis 
test was used to compare means for groups with unequal 
variances. Chi2 test for trends was used to determine 
trends over time. In order to identify risks factors for 
fungemia due to non-albicans Candida species, a multi-
nomial regression analysis was performed that analyzed 
parameters suggesting infection by a given species or by 
multiple species based on information available at the 
time of the positive blood culture. The most common 
species, i.e., C.  albicans, was used as reference to avoid 
blurring the picture by changing the reference for each 
species. All baseline variables representing pre-exist-
ing conditions before fungemia were first included in a 
full model and only risk factors significantly associated 
(p < 0.05) with at least one species were kept in the final 
model adjusted on the year of fungemia.
To identify risk factors associated with death (crude 
death rate at day 30 or day 8), backward stepwise logis-
tic regression models adjusted for the hospital and the 
year of inclusion were used for all patients and the three 
groups. First, non-colinear covariates with a p value 
under 0.25 in the univariate analysis were simultaneously 
entered into the models and then removed one by one 
until all of the covariates remaining in the reduced mod-
els had a p value under 0.05. Survivals were compared by 
the logrank test. Data were analyzed using Stata Statisti-
cal Software (version 12.0; College Station, TX).
Results
Characteristics of patients with candidemia according 
to the presence of malignancy and/or hospitalization 
in ICU
A total of 3417 adults were diagnosed with candidemia, 
for a total of 3572 episodes (Fig. 1). Almost half (47.2%) 
were hospitalized in ICU (Table 1). The 586 hematologi-
cal malignancies consisted mainly of lymphoma (41.8%) 
and acute leukemia (AL, 33.5%). Allogeneic hematopoi-
etic cell transplantation (HSCT, 10.9%) and graft ver-
sus host disease (5.1%) were recorded in hematology. 
The 1164 solid tumors involved the digestive (45.7%), 
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genital (12.3%), or urinary (8.9%) tract, or the ear, nose, 
and throat area (11.0%). Almost half (46.5%) of the 1667 
patients with no malignancy had recent surgery involv-
ing the digestive tract (364/775, 46.9%) or cardiovas-
cular invasive procedures (200/775, 25.8%), and the 
majority had a central venous catheter (64.6%). Hos-
pitalization in ICU was significatively more frequent 
in patients with no malignancy (1080/1667, 64.8%) 
compared to oncology (335/1164, 28.8%) or hematol-
ogy (199/586, 34.0%) patients (p < 0.0001). Recent sur-
gery was overall significantly more frequently recorded 
in ICU vs. outside ICU (Tables  1, S1), especially for 
patients with lymphoma (Table  S2) and those with 
digestive tumors (Table S3).
The most frequent first-line treatment was flucona-
zole (51.2%) or echinocandin (29.7%) with major differ-
ences according to the underlying disease and stay in ICU 
(Tables 1, S1–S3). Prescriptions were similar in vs. outside 
ICU for hematology patients but not in others. The pro-
portion of patients who received no antifungal drug was 
similar in the three groups whether in or outside ICU.
Species distribution and impact of ICU hospitalization 
and underlying disease
Of the 3666 isolates recovered, 737 (20.1%) were con-
sidered resistant to fluconazole. The vast majority (89%) 
was composed of C.  glabrata (76.1% of them) and 
C. krusei (all), and a few isolates of C. parapsilosis (7.5%), 
C. tropicalis (8.4%), and C.  albicans (0.8%). A caspo-
fungin MIC >0.25  µg/mL concerned 211 (6.5%) isolates 
including 41.5% of the C.  parapsilosis, and few C.  albi-
cans and C.  tropicalis (0.7% each), C.  glabrata (2.5%), 
C.  krusei (2.6%), and C.  kefyr (1.7%). The proportion of 
patients preexposed to antifungals was significantly 
higher in hematology (Table  1), especially those with 
AL (Table  S2), with no impact of ICU hospitalization. 
In oncology, the proportion of breakthrough infections 
was low and similar to that recorded in patients with no 
malignancy. However, oncology patients had twice as 
many breakthrough infections when in ICU compared 
to outside ICU, whereas the figures did not change for 
patients with no malignancy (Table S1).
Mixed infection accounted for 3.3% of all episodes, 
less frequently in hematology patients (Table 1). Species 
involved differed significantly (p < 0.001) between single 
and mixed infection, the latter involving predominantly 
C. albicans and C. glabrata (Fig. 1). The interval between 
sampling and blood culture positivity varied significantly 
with almost 40% of the cultures recovered after more 
than 3 days for C. glabrata compared to more than 40% 
of the cultures positive in less than 24 h for C. krusei, C. 
kefyr, and C. tropicalis (p < 0.0001, Fig. 3).
For single infections, species distribution varied sig-
nificantly with the underlying condition and stay in 
Fig. 1 Flow chart showing the incident and recurrent episodes of fungemia due to the six more common Candida species recorded during the 
YEASTS program, Paris, France (10/01/2002–12/31/2014)
655
ICU (Tables 1, S1–S3). C. albicans was the predominant 
species in all settings, but its proportion was signifi-
cantly lower in hematology patients compared to those 
with solid tumor or no malignancy. This decrease was 
observed specifically in patients with AL, especially in 
ICU where C.  albicans accounted for only 29.4% of the 
species compared to more than 50% in patients with 
other hematological malignancies including lymphoma. 
Candida tropicalis was almost as frequent as C. albicans 
in ICU patients with AL, and almost twice as much as in 
the other hematology patients outside ICU. ICU patients 
with lymphoma had very few C.  parapsilosis infec-
tions compared to those outside ICU, or to AL patients 
(Table S2), as did ICU patients with non-digestive tumors 
compared to those with digestive tumors, or to all oncol-
ogy patients outside ICU (Table S3). Overall, C. parapsi-
losis was less frequent in ICU than outside ICU in both 
hematology and oncology patients (Table  1). Candida 
glabrata was more frequent in oncology than in hema-
tology patients and those with no malignancy, and even 
more in ICU. The proportion of C.  glabrata was sig-
nificantly higher outside ICU in oncology patients with 
digestive tumor than in those without, whereas it was 
similar in ICU. Finally, C.  kefyr was more frequent in 
hematology patients, whether in ICU or not (Table 1).
The multinomial analysis uncovered independent fac-
tors that were associated with a given species (Table 2). 
Relative to patients infected by C. albicans, those infected 
by C.  glabrata were older, had more frequent diges-
tive tumors, and were less likely to have HIV infection. 
Those infected by C.  krusei had more frequent non-
digestive tumors, AL, or lymphoma, and less frequent 
surgery. Those infected by C.  parapsilosis were more 
often younger and male, had a central venous catheter, 
and were less likely to be hospitalized in ICU or to have 
HIV infection. Those with C. tropicalis were more often 
male, more likely suffering from AL or other hematologi-
cal malignancies. Those with C. kefyr were more likely to 
have AL and be 65–79 years old. Multiple species infec-
tion were more likely in the context of intravenous drug 
addiction, with a trend to be more likely in patients with 
central venous catheter and non-digestive solid tumors. 
Finally, preexposure to fluconazole was independently 
associated with infection by C.  glabrata and C.  krusei 
while preexposure to caspofungin predisposed to infec-
tion by C. glabrata, C. krusei, and C. parapsilosis.
Outcome
Survival was significantly decreased in ICU (Fig.  2, 
logrank test p < 0.0001). The crude death rate at day 30 
was overall increased in ICU and this was related to an 
increased rate in patients with no malignancy (Tables 1, 
S1). The crude day  30 death rate was similar when 
hospitalized in ICU and not influenced by the underly-
ing malignancy (Tables  S2–S3). The crude death rate at 
day 30 outside ICU was significantly increased in oncol-
ogy patients compared to others, and this was related to a 
significantly increase in delayed death rate (Table 1).
We then analyzed the independent risk factors for 
death following fungemia due to single species accord-
ing to its timing and to the groups (Tables 3, S4). For the 
entire population and each group, the lack of antifungal 
drug prescription and hospitalization in ICU (the latter 
not for early death in hematology and oncology patients) 
were identified as risk factors for death. The odds of 
death at day 30 was increased in oncology patients com-
pared to patients with no malignancy. Compared to 
C. albicans, C. glabrata and C. parapsilosis were associ-
ated with a decreased risk of day 8 and day 30 deaths (all 
patients, oncology patients), while only C.  parapsilosis 
was in patients with no malignancy (day  8 and day  30). 
Of note, the risk of early death was 3.07 (p = 0.052) for 
C.  kefyr infection in oncology patients. The species had 
no influence on the risk of death for hematology patients. 
Recent surgery was associated with a decreased risk of 
day 8 (all patients) and day 30 death (all patients, oncol-
ogy, no malignancy), while preexposure to echinocandins 
was associated with an increased risk of death in patients 
with no malignancy.
Trends over a decade
There was no significative trend over time for the major 
characteristics of the patients, including the propor-
tion of older patients, lymphoma, and HSCT among 
the hematological malignancies, or of digestive origin 
among the solid tumors. Preexposure to antifungals did 
Fig. 2 Survival rate after candidemia according to the hospitalization 
in ICU or not in patients with solid tumor, hematological malignancy, 
or no malignancy. Kaplan–Meier curves. YEASTS program, Paris area 
(October 2002–December 2014)
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not vary for fluconazole, whereas preexposure to echi-
nocandins significantly increased in the global popula-
tion, and in the three groups, but only in ICU (chi2 for 
trends, p =  0.015 for hematology, p =  0.022 for oncol-
ogy, and p  =  0.0395 for no malignancy). The propor-
tion of C. parapsilosis significantly decreased in patients 
with solid tumor (from 15.4% to 5.6%, p = 0.026). There 
was no increase in the proportion of resistant isolates 
among those of species intrinsically susceptible to flu-
conazole or caspofungin. After candidemia diagnosis, 
fluconazole first-line prescription decreased (from 59.8% 
to 29.8%, p < 0.0001), while echinocandin first-line ther-
apy increased (from 4.9% to 57.6%, p < 0.0001), with the 
same trends observed when analyzing specifically the 
three groups. Finally, there was no trend in crude mortal-
ity among hematology patients in or outside ICU. There 
Table 1 Comparison of major characteristics according to hospitalization outside (n = 1803) or in  (n = 1614) intensive 
care unit (ICU) in three major populations (hematological malignancy, solid tumor, or no malignancy) of adult patients 
with incident candidemia due to common species (YEASTS program, Paris area, Oct 2002–Dec 2014)
Data are mean ± SD or n/N (%)—denominator is specified when data are missing
a Denominator represents the number of patients for whom the positivity of the blood culture was known before death and/or for whom the information about 
treatment was recorded
b Precise date of death was missing, preventing definition of “early death” or “late death” in the corresponding patients
Outside ICU In ICU
Hematology
(n = 387)
Oncology
(n = 829)
No malignancy
(n = 587)
p Hematology
(n = 199)
Oncology
(335)
No malignancy
(n = 1080)
p
Age (mean ± SD) 54 ± 18 63 ± 14 60 ± 21 0.0001 57 ± 16 64 ± 13 59 ± 17 0.0001
Male gender 217 (56.1%) 496 (59.8%) 347 (59.1%) 0.455 133 (56.8%) 209 (62.4%) 652 (60.4%) 0.214
Recent surgery 
(<30 days)
20 (5.2%) 295 (35.6%) 246 (41.9%) <0.0001 20 (10.1%) 194 (57.9%) 529 (49.0%) <0.0001
Central venous 
catheter
329 (85.0%) 657 (79.3%) 269 (45.8%) <0.0001 165 (82.9%) 268 (80.0%) 808 (74.8%) 0.014
Previous antifungal 
treatment
72 (18.6%) 39 (4.7%) 41 (7.0%) <0.0001 49 (24.6%) 32 (9.6%) 96 (8.9%) <0.0001
 Fluconazole 22 (5.7%) 30 (3.6%) 25 (4.3%) 0.252 19 (9.6%) 20 (6.0%) 58 (5.4%) 0.075
 Echinocandins 30 (7.8%) 6 (0.7%) 8 (1.4%) <0.0001 17 (8.5%) 7 (2.1%) 22 (2.0%) <0.0001
Type of infection
 Single pathogen (n = 382) (n = 789) (n = 568) (n = 195) (n = 321) (n = 1048)
  C. albicans 187 (49.0%) 444 (56.3%) 339 (59.7%) 0.005 97 (49.7%) 179 (55.8%) 604 (57.6%) 0.122
  C. glabrata 42 (11.0%) 156 (19.8%) 97 (17.1%) 0.001 32 (16.4%) 79 (24.6%) 200 (19.1%) 0.041
  C. parapsilosis 64 (16.8%) 91 (11.5%) 78 (13.7%) 0.047 14 (7.2%) 22 (6.9%) 113 (10.8%) 0.054
  C. tropicalis 54 (14.1%) 62 (7.9%) 44 (7.8%) 0.001 34 (17.4%) 20 (6.2%) 93 (8.9%) <0.0001
  C. krusei 20 (5.2%) 24 (3.0%) 7 (1.2%) 0.002 10 (5.1%) 14 (4.4%) 24 (2.3%) 0.035
  C. kefyr 15 (9.9%) 12 (1.5%) 3 (0.5%) <0.0001 8 (4.1%) 7 (2.2%) 14 (1.3%) 0.028
 Multiple pathogens 5 (1.3%) 40 (4.8%) 19 (3.2%) 0.007 4 (2.0%) 14 (4.2%) 32 (3.0%) 0.341
First‑line treatment 
after diagnosis
(n = 348) (n = 709) (n = 275) (n = 111) (n = 265) (n = 809)
 Fluconazole 104 (29.9%) 460 (64.9%) 275 (58.9%) <0.0001 45 (28.5%) 121 (49.6%) 411 (50.8%) <0.0001
 Echinocandins 144 (41.4%) 135 (19.0%) 107 (22.9%) <0.0001 67 (42.4%) 86 (35.3%) 273 (33.8%) 0.114
 Others (including 
combination)
74 (21.3%) 52 (7.3%) 53 (11.4%) <0.0001 36 (22.8%) 27 (11.1%) 75 (9.3%) <0.0001
 No treatment 26 (4.5%) 62 (8.7%) 32 (6.9%) 0.475 10 (6.3%) 10 (4.1%) 50 (6.2%) 0.451
Death ratea
 Overall death at 
day 30
111/377(29.4%) 265/760 
(34.9%)
119/529 
(22.5%)
<0.0001 98/191 (51.3%) 150/312 (48.1%) 524/1036 (50.6%) 0.699
 Early death 
(<day 8)b
57/376 (15.2%) 130/757 (17.2%) 68/525 (13.0%) 0.119 65/190 (34.2%) 94/310 (30.3%) 334/1030 (32.4%) 0.645
 Late death 
(between days 
8–30)
53/376 (14.1%) 132/757 
(17.4%)
47/525 (9.0%) <0.0001 32/190 (16.8%) 54/310 (17.4%) 184/1030 (17.9%) 0.937
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was a significant trend towards an increase in day  30 
(from 18.2% to 58.3%, p = 0.0321) and day 8 (from 9.1% 
to 41.7%, p = 0.0047) deaths among oncology patients in 
ICU, but not outside ICU, and no trend observed among 
patients with no malignancy.
Discussion
We used a prospective multicentric hospital-based sur-
veillance program to analyze whether fungemia due to 
common Candida species differed depending on the 
underlying disease and what the impact of ICU hospi-
talization was. Malignancies currently represent approxi-
mately 35% of underlying diseases during candidemia [7, 
26] lower than what we found (50.5%). Candidemia rep-
resents approximately 30% of invasive fungal infections 
in hematology patients [27], mostly in those with AL [28, 
29], whereas a predominance of lymphoma was observed 
here. The incidence of fungemia (90% candidemia) is 
reported at 0.23%/145,030 admissions in 13 European 
cancer centers [19] and at 0.14% in nine hematology cent-
ers in Greece [18]. In France, an incidence of 2.5/100,000 
population/year was reported with significant increase in 
the hematology and oncology populations [30].
Overall, a higher proportion of C. tropicalis and C. kru-
sei [7, 31–34], C.  kefyr [35], and sometimes C.  glabrata 
[32] fungemia is found in hematology, and multi-species 
episodes are more frequent in oncology [36]. We and oth-
ers evidenced the impact of preexposure to antifungals 
on the distribution of Candida species [22, 37, 38], and 
that duration of fluconazole exposure influences the risk 
of C. krusei fungemia in hematology [6, 39]. We observed 
less C. albicans in hematology, that being related to AL 
patients. Less C. parapsilosis was observed in ICU, which 
may reflect more drastic hygiene procedures there. These 
observations were reinforced by those of the multino-
mial analysis demonstrating independent factors of being 
infected by a given Candida species.
Crude mortality at day 30 in hematology patients was 
comparable to former series [18, 40]. It was higher for 
oncology patients than for the other two groups out-
side ICU, and hospitalization in ICU increased mor-
tality. One may speculate that the better early outcome 
found in patients with AL outside ICU may be related 
to early empiric antifungal therapy administered during 
prolonged febrile neutropenia. However, crude mortal-
ity in ICU was not influenced by underlying disease, 
which suggests that organ failure(s) was (were) probably 
the major determinant(s) of outcome. The worrisome 
trend in the evolution of candidemia mortality that we 
reported in ICU [9] is explained by the outcome in oncol-
ogy patients, suggesting that specific actions should now 
be focused on this currently rising population. One can 
hypothesize that the oncology patients sent to ICU now 
have more severe illnesses. Using the multivariate analy-
sis, we showed that the independent risk factors for death 
varied depending on the underlying disease. In hematol-
ogy patients, the species recovered from blood culture 
did not influence death nor did the type of hematological 
malignancy, while the age and hospitalization in ICU did. 
In oncology patients and in patients with no malignancy, 
other factors influenced survival.
Being infected by C.  parapsilosis or C.  glabrata was 
independently associated with a more favorable outcome. 
In the multinomial analysis, we found that, in comparison 
Fig. 3 Proportion of each species identified in blood cultures found positive less than 24 h, between 1 and 3 days, and more than 3 days after 
sampling
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Table 2 Risk factors for  fungemia due to  C.  glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. kefyr or multiple species 
in reference to fungemia due to C. albicans (n = 1850), multivariate multinomial regression analysis (YEASTS program, 
Paris area, October 2002–December 2014)
C. glabrata C. krusei C. parapsilosis
OR 95% CI p OR 95% CI p OR 95% CI p
Male sex 0.86 0.71–1.04 0.116 1.37 0.88–2.14 0.163 1.58 1.24–2.01 <0.0001
Age (years)
 <45 1 1 1
 45–64 1.25 0.92–1.70 0.146 0.86 0.09–1.53 0.615 0.67 0.49–0.90 0.007
 65–79 1.34 0.98–1.84 0.064 0.68 0.36–1.29 0.238 0.46 0.33–0.65 <0.0001
 ≥80 1.77 1.23–2.56 0.002 0.69 0.28–1.74 0.436 0.42 0.26–0.67 <0.0001
ICU 1.22 0.99–1.50 0.060 1.43 0.91–2.27 0.122 0.64 0.49–0.82 0.001
Recent surgery (<30 days) 0.94 0.76–1.14 0.516 0.55 0.33–0.92 0.024 0.89 0.69–1.15 0.387
Underlying disease
 No malignancy 1 1 1
 Digestive tumor 1.62 1.24–2.12 <0.0001 1.48 0.70–3.12 0.304 0.79 0.54–1.14 0.206
 Other solid tumor 1.01 0.76–1.33 0.948 2.45 1.35–4.45 0.003 0.75 0.53–1.06 0.101
 Acute leukemia 1.11 0.66–1.88 0.682 3.36 1.49–7.55 0.003 1.22 0.74–2.00 0.440
 Lymphoma 0.81 0.54–1.24 0.338 2.28 1.09–4.76 0.028 0.66 0.41–1.07 0.095
 Other hematological malignancy 0.60 0.34–1.06 0.079 1.48 0.53–4.15 0.456 0.78 0.43–1.39 0.394
Central venous catheter 0.88 0.71–1.09 0.244 1.30 0.75–2.26 0.344 1.44 1.08–1.92 0.012
HIV infection 0.55 0.31–0.99 0.046 0.36 0.10–1.27 0.114 0.50 0.27–0.94 0.032
Intravenous drug addiction 1.04 0.34–3.21 0.941 NC 0.36 0.08–1.62 0.183
Preexposure to antifungal drugs
 Fluconazole 2.42 1.63–3.59 <0.0001 6.17 3.44–11.07 <0.0001 1.03 0.58–1.85 0.919
 Echinocandins 3.45 1.88–6.33 <0.0001 3.70 1.40–9.80 0.009 5.79 3.22–10.43 <0.0001
C. tropicalis C. kefyr Multiple species
OR 95% CI p OR 95% CI p OR 95% CI p
Male sex 1.51 1.16–1.97 0.002 0.90 0.52–1.55 0.706 0.95 0.64–1.42 0.812
Age (years)
 <45 1 1 1
 45–64 1.32 0.91–1.93 0.143 1.84 0.72–4.73 0.201 1.01 0.54–1.89 0.963
 65–79 1.14 0.95–2.10 0.085 3.18 1.24–8.16 0.016 1.11 0.58–2.12 0.754
 ≥80 0.99 0.58–1.71 0.982 0.77 0.15–4.07 0.762 1.51 0.70–3.24 0.289
ICU 1.08 0.82–1.41 0.594 1.56 0.88–2.78 0.132 0.96 0.62–1.48 0.839
Recent surgery (<30 days) 0.83 0.62–1.10 0.200 0.83 0.43–1.58 0.567 0.96 0.63–1.47 0.867
Underlying disease
 No malignancy 1 1 1
 Digestive tumor 0.73 0.47–1.14 0.169 1.93 0.82–4.58 0.134 1.52 0.85–2.69 0.155
 Other solid tumor 0.98 0.68–1.43 0.936 1.63 0.71–3.76 0.248 1.70 1.00–2.90 0.051
 Acute leukemia 4.16 2.58–6.70 <0.0001 12.36 5.15–29.64 <0.0001 0.82 0.24–2.83 0.753
 Lymphoma 1.28 0.79–2.07 0.318 2.55 0.93–7.00 0.069 0.14 0.02–1.04 0.055
 Other hematological malignancy 1.71 1.01–3.06 0.044 1.31 0.28–6.04 0.732 1.25 0.46–3.36 0.663
Central venous catheter 1.03 0.77–1.39 0.822 0.75 0.40–1.41 0.373 1.66 1.00–2.76 0.052
HIV infection 0.95 0.51–1.75 0.857 0.46 0.59–3.61 0.461 0.82 0.27–2.50 0.730
Intravenous drug addiction 1.74 0.56–5.41 0.341 NC 8.31 2.82–24.49 <0.0001
Preexposure to antifungal drugs
 Fluconazole 1.14 0.63–2.08 0.668 1.95 0.67–5.76 0.223 0.50 0.12–2.08 0.340
 Echinocandins 0.33 0.08–1.43 0.137 2.74 0.75–10.09 0.129 1.59 0.35–7.22 0.551
OR adjusted odd ratio for year, 95% CI odd ratio 95% confidence interval, NC non-calculable
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to those infected by C. albicans, patients with C. glabrata 
infections were more often very old, more often had 
digestive tumors, and were more often preexposed to 
echinocandins or fluconazole. These factors were also 
independently associated with death at day 30. It is pos-
sible that the observation by others [41] that patients 
infected by C. glabrata have a higher crude mortality can 
be related to specificity of the cohort (249 patients with 
candidemia, 23 infected by C. glabrata) studied in several 
centers in 1992–1994 and to preexposure to antifungals, 
reflecting more severe cases as already described in the 
ICU population [42] rather than to the species itself. Evo-
lution of patients’ management may indeed at least par-
tially explain the discrepant results.
Recent studies found that antifungal treatment was an 
independent factor decreasing both early and late death 
[31] and that echinocandins as first-line therapy reduced 
death rate [43]. As already reported [44] and shown 
here, a major observation is that a constant risk factor 
for death was the lack of antifungal prescription despite 
knowledge of the blood culture positivity, with no influ-
ence of the initial antifungal choice. In contrast to what 
is observed in the USA [7, 45], resistance to antifungals 
is not yet of concern in our area, with overall less than 
1% resistance to caspofungin in isolates not identified as 
C. parapsilosis, less than 2.3% resistance to fluconazole in 
isolates not identified as C. krusei or C. glabrata, and no 
increase in these figures over time. Thus, we would rec-
ommend early prescription of antifungals based on the 
most likely species and the known susceptibility profile 
of its wild-type isolates rather than waiting for the pre-
cise identification and a fortiori for MIC determination. 
It may later be appropriate to switch to a more adapted 
treatment as recently validated in ICU [46].
Table 3 Independent factors associated with death before day 8 or before day 30 in all adult patients with incident epi-
sode of fungemia due to single isolate of common Candida species (YEATS program, Paris area, 2002–2014)
a Other variables included in full model (with p < 0.25 in univariate analysis of early death) not conserved because not significant: allo-BMT, male gender, and type of 
underlying disease
b Male gender included in the model but not conserved because not significant
c OR adjusted for hospital and year (introduced in the model as dummy variable)
Death before day 8a Death before day 30b
ORc 95% CI p ORc 95% CI p
Age category (years)
 <45 1 1
 45–64 1.39 0.94–2.05 0.101 0.0073 1.59 1.20–2.09 0.001
 65–79 1.76 1.18–2.62 0.005 2.13 1.60–2.84 <0.0001 <0.0001
 ≥80 2.11 1.30–3.41 0.002 2.92 2.05–4.15 <0.0001
Hospitalization in ICU 2.39 1.84–3.12 <0.0001 2.47 2.03–3.01 <0.0001
Recent surgery (≤30 days) 0.75 0.57–0.97 0.031 0.66 0.54–0.80 <0.0001
Underlying disease
 No malignancy 1
 Digestive tumor 1.42 1.08–1.85 0.012
 Non‑digestive tumor 1.42 1.10–1.84 0.007 0.00487
 Acute leukemia 1.06 0.70–1.62 0.773
 Lymphoma 1.25 0.88–1.78 0.214
 Other hematological malignancy 0.99 0.64–1.56 0.982
Species recovered from blood culture
 C. albicans 1 1
 C. glabrata 0.61 0.43–0.89 0.009 0.69 0.54–0.89 0.004
 C. parapsilosis 0.30 0.17–0.52 <0.0001 <0.0001 0.49 0.35–0.67 <0.0001 <0.0001
 C. tropicalis 1.00 0.67–1.49 0.999 1.00 0.74–1.34 0.987
 C. krusei 1.24 0.62–2.44 0.544 1.52 0.91–2.54 0.106
 C. kefyr 1.79 0.84–3.80 0.132 1.36 0.74–2.53 0.325
Initial antifungal treatment
 Fluconazole alone 1 1
 Echinocandin alone 1.02 0.74–1.41 0.909 <0.0001 1.08 0.86–1.36 0.517 <0.0001
 Other treatments 0.75 0.46–1.21 0.234 0.84 0.62–1.15 0.283
 No antifungal drug 10.96 7.60–15.81 <0.0001 4.94 3.51–6.95 <0.0001
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The limitations of our database are the restriction to 
one city, the lack of information regarding severity of ill-
ness, the duration of candidemic period, central venous 
catheter removal [26], lack of consideration of antifungal 
dosing issues [47–49], and delayed initiation of adequate 
antifungal therapy [47, 50, 51], concomitant mold infec-
tions, or bacteremia.
Even if we are fully aware that characteristics of can-
didemia are highly variable, especially in terms of spe-
cies distribution, we think that our data are relevant for 
hematologists, oncologists, and ICU physicians practic-
ing in the Western world. Indeed, characteristics and 
risk factors for death during candidemia differ in patients 
with hematological malignancies from those with solid 
tumors. Furthermore, the odds of infection by a given 
Candida species was influenced not only by host under-
lying disease but also by hopitalization in ICU and preex-
posure to antifungal drugs.
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